Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CORT vs SYRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CORT Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

CORT Overall Winner 6-Pillar Tally: CORT 5 – 0 SYRE (1 Tie) Matrix Metrics: CORT 7 – 3 SYRE

As of Nov 16, 2026, Corcept Therapeutics Inc. (CORT) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CORT carries a Unified Composite Score of 50.7/100 (HOLD) at $69.17 (14.6x Forward P/E, 11.5% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: CORT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.3); meanwhile SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CORT vs SYRE
CORT NASDAQ Head-to-Head Winner
Corcept Therapeutics Inc.
Pharmaceutical Preparations
$69.17
-5.17% 1D
Market Cap $8.1B
TTM Revenue $964M
Forward P/E 14.6x
Beta / 30D Vol 1.63β · 85% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 45.0 Fund 55.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.1%), weak momentum, RSI 23
RSI-14: 23.3 · SMA20: $83.94 · SMA50: $102.85
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70

6-Pillar Scorecard Institutional Category Breakdown (CORT 5 – 0 SYRE)

Columns: Metric · CORT · SYRE
1. Valuation Multiples CORT
Forward P/E 14.6x N/M
Trailing P/E 55.4x N/M
PEG Ratio 0.81x N/M
EV / Revenue 8.3x N/M
2. Growth & Scale CORT
Revenue Growth (YoY) +64.0% +0.0%
Earnings Growth (YoY) +531.3% -99.7%
TTM Revenue (USD) $964M N/A
Market Cap $8.1B $9.8B
3. Profitability & Quality CORT
Gross Margin 98.5% N/A
Operating Margin 11.5% 0.0%
Net Profit Margin 16.8% 0.0%
Return on Equity (ROE) 22.1% -35.0%
4. Balance Sheet & Cash Flow CORT
Cash Generation (TTM) $195M N/A
Cash Flow Margin 20.2% N/A
Net Cash / Leverage $90M Net Cash $10.06 Book/Sh · -35.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CORT
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 53.1% (10th %ile) 87.9% (10th %ile)
Put/Call OI Skew 0.41x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CORT (7) vs SYRE (3)
Institutional Metric CORT SYRE Criterion Row Edge
Market Capitalization
Scale
$8.1B $9.8B Larger Scale SYRE
Trailing P/E Ratio
Valuation
55.4x N/M Lower Multiple CORT
Forward P/E Ratio
Valuation
14.6x N/M Lower Multiple CORT
Revenue Growth (YoY)
Growth
+64.0% +0.0% Higher Growth CORT
Operating Margin (TTM)
Profitability
11.5% 0.0% Higher Margin CORT
Net Profit Margin
Profitability
16.8% 0.0% Higher Margin CORT
Return on Equity (ROE)
Capital Efficiency
22.1% -35.0% Higher ROE CORT
52-Week Range Position
Momentum
42% ($29–$126) 88% ($22–$111) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.63β · 85% Vol 1.75β · 59% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
50.7 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite CORT
Trailing 12M Revenue (USD)
Operating Scale
$964M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
98.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.81x PEG · 8.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$195M ($90M Net Cash) N/A ($10.06 Book/Sh · -35.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +62.32 pp
CORT: -37.21% · SYRE: +25.11%
3M Horizon SYRE +34.14 pp
CORT: -41.43% · SYRE: -7.29%
6M Horizon SYRE +17.15 pp
CORT: +25.49% · SYRE: +42.64%
1Y Horizon SYRE +350.43 pp
CORT: -8.69% · SYRE: +341.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CORT vs SYRE. Trailing 12-month operating profitability (CORT 11.5% vs SYRE 0.0%) and valuation multiples (CORT 14.6x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CORT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$964M
Gross Margin98.5%
Op. Margin11.5%
ROE / Fwd P/E22.1% · 14.6x
SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CORT CONSOLIDATION
109d in phase · OBV DISTRIBUTION
Current IV 53.1%
IV Percentile 10th %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CORT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CORT Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $8.1B market capitalization and 11.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CORT vs SYRE Key Questions & Quantitative Answers

As of Nov 16, 2026, Corcept Therapeutics Inc. (CORT) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CORT carries a Unified Composite Score of 50.7/100 (HOLD) at $69.17 (14.6x Forward P/E, 11.5% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CORT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.3); meanwhile SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CORT leads the Growth & Scale pillar: CORT posts +64.0% YoY revenue growth and +531.3% YoY earnings growth on $964M TTM revenue (98.5% gross margin, 11.5% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CORT generates $964M in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, CORT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.

CORT screens cheaper on headline valuation multiples. CORT trades at 14.6x Forward P/E, 55.4x Trailing P/E, 0.81x PEG, and 8.3x EV/Revenue (20.2% FCF margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CORT (22.1% ROE) versus SYRE (-35.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CORT carries 53.1% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.63β · 85% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.